ImmPACT Bio is now part of Lyell Immunopharma. Learn how we are continuing to advance next-generation cell therapies that offer patients improved outcomes @Lyell or www.lyell.com.
About ImmPACT Bio: ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies that address key biological challenges in treating cancer and autoimmune diseases.
Our technology is designed to precisely distinguish cancer and diseased cells from normal cells; thereby eliminating them without damaging normal tissues.
The company was founded in 2017 in the FuturRx incubator (Israel).
In 2019, ImmPACT Bio was incorporated in the US. In 2021 ImmPACT Bio merged with Kalthera.
In 2022 we moved our Corporate offices to West Hills, CA and built a state-of-the-art clinical manufacturing facility.
Company Details
- Employees
- 64
- Address
- 8501 Fallbrook Ave, 200,israel
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://immpactbio.com
- Keywords
- CAR-T, Immunotherapy, Cancer Therapy, On target off tumor toxicity, Selective treatment, Logic gate, Oncology, Biotechnology, Research, Immunotherapy, autoimmune, lupus.
- HQ
- West Hills, California
Immpact Bio Questions
Immpact Bio's website is http://immpactbio.com
Immpact Bio's LinkedIn profile is https://www.linkedin.com/company/immpact-bio
Immpact Bio has
64 employees.
View email and phone details for 64
employees at Immpact Bio.
Immpact Bio's industry is
Biotechnology Research
Immpact Bio's top competitors are
Lyell Immunopharma,
Allogene Therapeutics,
Neogene Therapeutics,
Immunitybio, Inc.,
Kite Pharma,
Capsida Biotherapeutics,
Poseida Therapeutics, Inc.,
Atara Biotherapeutics,
A2 Biotherapeutics, Inc.,
Appia Bio.
Immpact Bio's categories are Biotechnology Research
